Mr. Cameron Groome reports

MICROBIX & SEEGENE USA JOINTLY ENHANCING LAB TEST ACCURACY

Microbix Biosystems Inc. has arranged a collaboration with Seegene USA Inc., a leading developer of multiplex molecular assays and automated solutions for U.S. labs. Under the parties' collaboration, Seegene USA will distribute and recommend Microbix's Quality Assessment Products ("QAPs") to monitor the workflow accuracy of Seegene Novaplex and Allplex assays in use across the United States.

Microbix QAPs are available to support PCR-based (molecular) assays formatted on Copan FLOQSwabs and room-temperature stable, or in liquid vial format that are refrigerator-temperature stable. Microbix PROCEEDx brand QAPs are Research Use Only "RUO" samples, while its REDx brand QAPs are In-Vitro Diagnostic "IVD" Controls. Regular use of QAPs helps ensure the accuracy of laboratory-conducted assays.

With this agreement, Seegene USA will begin offering Microbix's QAPs products, alongside its current portfolio of high multiplex PCR assays that test for infectious disease pathogens under its Allplex and Novaplex brands. These assays, using Seegene proprietary technology, are unique in their ability to produce high-multiplex results from a single channel in a PCR reaction. In combination, US labs receive an efficient, low-cost approach to achieve high-quality syndromic testing for infectious disease pathogens when compared to currently available options.

Philip Casselli, SVP Business Development, commented, "Our longstanding relationship with Seegene Canada laid a strong foundation for this Microbix - Seegene USA relationship. Our collaboration naturally aligns the two companies to help assure optimal results for laboratories performing high-multiplex PCR testing using Seegene Assays. This week we began our training and comprehensive support of the Seegene USA team."

"In this partnership, we are again increasing our IVD presence for the U.S. and further supporting our lab customers in their mission to better provide quality results for their patients and institutions," said Craig Howell, SVP for Marketing of Seegene USA, Inc. "As well, we believe our ongoing IVD assay development requires custom control and validation panel expertise that is met by Microbix's competencies."

About Microbix Biosystems Inc.

Microbix Biosystems creates proprietary biological products for human health, with over 100 skilled employees and annualized sales targeting $2-million per month. It makes a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers while QAPs are sold to clinical lab accreditation organizations, diagnostics companies and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of 10 international distributors. Microbix is ISO 9001 and ISO 13485 accredited, U.S. FDA (U.S. Food and Drug Administration) registered, Australian TGA (Therapeutic Goods Administration) registered, and Health Canada establishment licensed, and it provides CE-marked (Conformite Europeenne) products.

We seek Safe Harbor.